Marston NA, Gurmu Y, Melloni GEM, et al. - Since there exists uncertainty regarding the link between cholesterol levels and risk of venous thromboembolism (VTE), therefore, researchers investigated the influence of PCSK9 inhibition on the risk of VTE, looked at the potential mechanisms, as well as assessed the efficacy in clinically and genetically described risk subgroups. For this purpose, a post-hoc analysis of the FOURIER trial as well as a meta-analysis combining data from FOURIER and ODYSSEY OUTCOMES was conducted. Findings revealed that a significant reduction in the risk of VTE was brought about by PCSK9 inhibition. Experts noted that evolocumab led to a decrease in Lp(a) by 33 nmol/L and risk of VTE by 48% in patients exhibiting higher baseline Lp(a) levels, whereas it caused decreased Lp(a) by only 7 nmol/L and had no impact on VTE risk in patients exhibiting lower baseline Lp(a) levels. Overall, Lp(a) decrease may be a crucial mediator of this effect.